Moleculin Targets accelerated FDA approval of WP1732; Pursues Development for Ocular Tumors

by in

Moleculin announced that it has entered into an agreement with the Jagiellonian University in Krakow, Poland, for the development of its STAT3 inhibitor, WP1732, for the treatment of ocular tumors.